CEL-SCI Corporation (CVM) Stock Analysis
A live, multi-source view of CEL-SCI Corporation (CVM): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About CEL-SCI Corporation
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Sector: Healthcare · Industry: Biotechnology · United States · cel-sci.com
Key statistics · as of 2026-09-05
As of 2026-09-05, CEL-SCI Corporation (CVM) had a market capitalization of $28.7M (forward -0.3) and a beta of 0.62; the shares traded in a 52-week range of $0.89 – $11.51 (-84.7% over the year).
- Market cap
- $28.7M
- Enterprise value
- $30.0M
- Forward P/E
- -0.3
- PEG ratio
- 1.12
- Price / book
- 2.62
- EPS (trailing)
- $-1.69
- EPS (forward)
- $-6.38
- Payout ratio
- 0.0%
- Ex-dividend date
- 1996-08-28
- 52-week range
- $0.89 – $11.51
- 52-week change
- -84.7%
- Beta
- 0.62
- Average volume
- 314,725
- Shares outstanding
- 17.6M
- Short % of float
- 4.19%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, CEL-SCI Corporation (CVM) last closed at $1.54 (the last completed close before that scan).
Technicals at the scan: RSI 51 (neutral territory), price -1.3% versus its 20-day average, 20-day versus 50-day average spread +12.2%, MACD histogram -0.01.
Sentiment inputs: StockTwits 58% bullish.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of CVM; corporate insiders filed 1 buy and 0 sells (1 filer, latest disclosure 2026-08-26). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Geert R. Kersten (1B/0S). Who is trading what
RapidTradeView pick record
CVM has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls CEL-SCI Corporation (CVM) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell CVM.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.